Hyloris remains on-track to broaden its product pipeline to its target of 30 product candidates and marketed products by 2024, delivering a confident-half year update in the face of some pushback from the US Food and Drug Administration.
Hyloris On Track To Meet 2024 Target During Half-Year Update
Company Aims To Expand Its Portfolio To 30 Products By 2024
Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.
More from Earnings
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
• By
Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.